8-K: Jazz Pharma Ziihera Shines in Phase 3 GEA Trial

Jazz Pharmaceuticals announced positive top-line results from its Phase 3 HERIZON-GEA-01 trial for Ziihera in HER2-positive gastroesophageal adenocarcinoma.

Summary

• Jazz Pharmaceuticals plc announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera (zanidatamab-hrii) for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).
• Ziihera in combination with chemotherapy, and Ziihera plus the PD-1 inhibitor Tevimbra (tislelizumab) and chemotherapy, were evaluated as first-line treatments.
• Both Ziihera plus chemotherapy and Ziihera plus tislelizumab and chemotherapy demonstrated highly statistically significant and clinically meaningful improvements in progression-free survival (PFS) compared to the control arm (trastuzumab plus chemotherapy).
• Ziihera plus tislelizumab and chemotherapy also showed clinically meaningful and statistically significant improvements in overall survival (OS) compared to the control arm.
• Ziihera plus chemotherapy demonstrated a clinically meaningful effect with a strong trend toward statistical significance for OS at the first OS interim analysis.
• A PFS and OS benefit was observed in the Ziihera plus tislelizumab and chemotherapy arm versus the control arm in both PD-L1 positive and PD-L1 negative subgroups.
• Improvements were also seen in key secondary endpoints, including objective response rate (ORR) and duration of response (DoR), for both Ziihera combination regimens.
• The safety profile of Ziihera in combination with chemotherapy, with or without tislelizumab, was generally consistent with the known safety profile of each agent, with no new safety signals observed.

Sentiment

Score: 9

Explanation: The filing reports highly positive, statistically significant, and clinically meaningful Phase 3 trial results for Ziihera in a significant oncology indication, with plans for sBLA submission and potential new standard of care designation. This is a major positive development for the company's pipeline and future revenue potential.

Positives

• Ziihera plus chemotherapy achieved clinically meaningful and statistically significant progression-free survival (PFS) improvement over trastuzumab and chemotherapy.
• Ziihera plus chemotherapy showed a clinically meaningful effect with a strong trend toward statistical significance for overall survival (OS) at the first interim analysis.
• Ziihera plus tislelizumab and chemotherapy demonstrated clinically meaningful and statistically significant improvements in both OS and PFS over trastuzumab and chemotherapy.
• PFS and OS benefits were observed across both PD-L1 positive and PD-L1 negative subgroups for the Ziihera plus tislelizumab and chemotherapy arm.
• Improvements in objective response rate (ORR) and duration of response (DoR) were observed for both Ziihera combination regimens versus the control arm.
• The safety profile was consistent with known profiles of each agent, with no new safety signals observed in the investigational combination arms.

Risks

• ZIIHERA can cause embryo-fetal harm; advise patients of the risk and need for effective contraception.
• ZIIHERA can cause decreases in left ventricular ejection fraction (LVEF); LVEF declined by >10% and decreased to <50% in 4.3% of 233 patients in clinical studies.
• Left ventricular dysfunction (LVD) leading to permanent discontinuation of ZIIHERA was reported in 0.9% of patients.
• ZIIHERA can cause infusion-related reactions (IRRs); an IRR was reported in 31% of 233 patients treated with ZIIHERA as a single agent, including Grade 3 (0.4%) and Grade 2 (25%).
• ZIIHERA can cause severe diarrhea; diarrhea was reported in 48% of 233 patients treated in clinical studies, including Grade 3 (6%) and Grade 2 (17%).
• Serious adverse reactions occurred in 53% of 80 patients with unresectable or metastatic HER2-positive BTC who received ZIIHERA, including biliary obstruction (15%), biliary tract infection (8%), sepsis (8%), pneumonia (5%), diarrhea (3.8%), gastric obstruction (3.8%), and fatigue (2.5%).
• A fatal adverse reaction of hepatic failure occurred in one patient who received ZIIHERA.
• Risks and uncertainties are associated with the successful completion of regulatory activities and uncertain regulatory approval.
• Risks are related to failure or delays in successfully initiating or completing clinical trials and assessing patients.

Future Outlook

Jazz Pharmaceuticals plans to engage with the FDA and expects to submit a supplemental Biologics License Application (sBLA) in the U.S. in the first half of 2026 to support Ziihera as a first-line treatment for HER2+ locally advanced or metastatic GEA. An additional overall survival (OS) interim analysis for the Ziihera plus chemotherapy arm is currently expected in mid-2026. The company also plans to submit these data for presentation at a major medical meeting in the first quarter of 2026, for publication in a peer-reviewed journal, and will rapidly submit for adoption in the National Comprehensive Cancer Network Guidelines (NCCN Guidelines).

Management Comments

• "Based on the positive results seen in the HERIZON-GEA-01 trial, the zanidatamab plus chemotherapy combination, with and without tislelizumab, has the potential to become the new standard of care for patients in HER2+ first-line locally advanced unresectable or metastatic GEA." Dr. Kohei Shitara, director of the Department of Gastrointestinal Oncology, and principal trial investigator at the National Cancer Center Hospital East, Kashiwa, Japan.
• "This is the first Phase 3 trial to demonstrate a benefit for a novel HER2-targeted therapy compared to trastuzumab as part of a combination regimen in HER2+ first-line GEA." Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals.
• "We believe these results will be practice changing, and highlight the potential impact of Ziihera for patients who are facing a devastating diagnosis and limited options in locally advanced or metastatic GEA." Rob Iannone.
• "We expect Ziihera to become the new standard of care anti-HER2 therapy for patients with HER2+ first-line metastatic GEA regardless of PD-L1 status." Rob Iannone.

Industry Context

Gastroesophageal adenocarcinoma (GEA) is the fifth most common cancer worldwide, with approximately 20% of patients having HER2+ disease. It remains an aggressive cancer with a poor prognosis and limited treatment options, with a global five-year survival rate of less than 30% for gastric cancer and about 19% for GEA. Ziihera's positive Phase 3 results represent a significant advancement as it is the first novel HER2-targeted therapy to demonstrate a benefit over trastuzumab in first-line HER2+ GEA, potentially establishing a new standard of care and addressing a high unmet medical need.

Comparison to Industry Standards

• Ziihera plus chemotherapy, with or without tislelizumab, demonstrated superior efficacy compared to the current standard of care, trastuzumab plus chemotherapy, in HER2+ first-line GEA.
• This marks the first Phase 3 trial where a novel HER2-targeted therapy has shown a benefit over trastuzumab as part of a combination regimen in HER2+ first-line GEA.
• The results suggest Ziihera could become the new standard of care anti-HER2 therapy for patients with HER2+ first-line metastatic GEA, regardless of PD-L1 status, potentially replacing or significantly augmenting existing trastuzumab-based regimens.

Stakeholder Impact

• Shareholders: Positive impact due to successful Phase 3 trial, potential for new market entry, and increased revenue streams from Ziihera.
• Patients: Significant positive impact by offering new, potentially more effective treatment options for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma, a disease with poor prognosis and limited options.
• Healthcare Providers: Provides a new potential standard of care, expanding the therapeutic arsenal for treating HER2+ GEA.

Next Steps

• Engage with the FDA for regulatory discussions.
• Submit a supplemental Biologics License Application (sBLA) in the U.S. in the first half of 2026 for Ziihera as a first-line treatment for HER2+ locally advanced or metastatic GEA.
• Submit data for presentation at a major medical meeting in the first quarter of 2026.
• Submit data for publication in a peer-reviewed journal.
• Rapidly submit for adoption in the National Comprehensive Cancer Network Guidelines (NCCN Guidelines).
• Continue the HERIZON-GEA-01 trial with an additional planned OS interim analysis for Ziihera plus chemotherapy expected in mid-2026.
• Continue ongoing research for Ziihera in other indications, including Phase 3 HERIZON-BTC-302 (biliary tract cancer), Phase 3 EmpowHER-303 (metastatic HER2+ breast cancer), DiscovHER PAN-206 (HER2+ cancers basket trial), and Phase 2 EmpowHER-208 (HER2+ neoadjuvant and adjuvant breast cancer).

Key Dates

Recommendation

The positive Phase 3 results for Ziihera in HER2+ GEA are highly significant, demonstrating statistically meaningful and clinically relevant improvements in both PFS and OS compared to the current standard of care. This positions Ziihera to become a new standard of care in a substantial oncology market with high unmet need. The clear path to sBLA submission in H1 2026, coupled with a consistent safety profile, de-risks a major pipeline asset and indicates strong future revenue potential. This news should drive significant positive re-rating of the stock.

Keywords

Jazz Pharmaceuticals, Ziihera, zanidatamab-hrii, HER2-positive, gastroesophageal adenocarcinoma, GEA, Phase 3, clinical trial, oncology, cancer treatment, Tevimbra, tislelizumab, progression-free survival, overall survival, sBLA, FDA, biopharma